SCS/DJZ:kam 6/12/02 4239-61858 121520

#3

Attorney Reference Number 4239-61858

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rice *et al.*

Art Unit: 1619

Application No. 10/017,323

Filed: December 13, 2001

For: BENZOYLALKYLINDOLEPYRIDINIUM COMPOUNDS AND PHARMACEUTICAL COMPOUNDS COMPRISING SUCH COMPOUNDS

Examiner: Not yet assigned

Date: June 12, 2002

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on June 12, 2002, as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON D.C. 20231.

Stacey C. Slater, Esq.
Attorney for Applicant

TRANSMITTAL LETTER

COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Enclosed for filing in the application referenced above are the following:

☒ Information Disclosure Statement
☒ Form 1449 and references cited thereon

☒ The Director is hereby authorized to charge any additional fees that may be required to Deposit Account No. 02-4550. A copy of this sheet is enclosed.

☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By
Stacey C. Slater, Esq.
Registration No. 36,011

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446
cc: Docketing

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rice *et al.*

Application No. 10/017,323

Filed: December 13, 2001

For: BENZOYLALKYLINDOLEPYRIDINIUM COMPOUNDS AND PHARMACEUTICAL COMPOUNDS COMPRISING SUCH COMPOUNDS

Examiner: Not yet assigned

Date: June 12, 2002

Art Unit: 1619

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on June 12, 2002 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

Stacey C. Slater, Esq.
Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Sir:

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents and several Russian-language documents. The relevance of the Russian-language documents is as shown in their titles and accompanying figures. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this Information Disclosure Statement, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Stacey C. Slater, Esq.
Registration No. 36,011

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Docket: 4239-61858	App: 10/117,323
	Applicant: Rice *et al.*	
	Filed: December 13, 2001	Art Unit:

U.S. PATENT DOCUMENTS

Init.*		Number	Date	Name	Class	Sub	Filed

FOREIGN PATENT DOCUMENTS

		Number	Date	Country	Class	Sub		

OTHER DOCUMENTS

			Abola, E.E., *et al.*, "*Crystallographic Databases – Information Content, Software Systems, Scientific Applications*," (Allen, F. H., Bergerhoff, G. & Sievers, R., eds), pp. 107-132, 1987.
			Baba, M., *et al.*, "Highly Specific Inhibition of Human Immunodeficiency Virus Type 1 by a Novel 6-Substituted Acyclouridine Derivative," *Biochem. Biophys. Res. Comm.* 165(3):1375-1381, Dec. 1989. ABSTRACT ONLY
			Bernstein, F.C., *et al.*, "The Protein Data Bank: A Computer-Based Archival File for Macromolecular Structures," *J. Mol. Biol.* 112:535-542 (1977).

EXAMINER:	DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Docket: 4239-61858	App: 10/827,323
	Applicant: Rice *et al.*	
	Filed: December 13, 2001	Art Unit:

OTHER DOCUMENTS

			Balzarini, J., *et al.*, "2',5'-Bis-*O*-(*tert*-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide)pyrimidine (TSAO) Nucleoside Analogues: Highly Selective Inhibitors of Human Immunodeficiency Virus Type 1 That are Targeted at the Viral Reverse Transcriptase," *Proc. Natl Acad. Sci USA* 89:4392-4396, May 1992.
			Buckheit, Jr., R.W., *et al.*, "Highly Potent Oxathiin Carboxanilide Derivatives with Efficacy against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Isolates," *Antimicrob. Agents Chemother.* 41(4):831-837, Apr. 1997.
			Bundgaard, H., *et al.*, "A Novel Solution-Stable, Water-Soluble Prodrug Type for Drugs Containing a Hydroxyl or an NH-Acidic Group," *J. Med. Chem.* 32(12):2501-2507, Dec. 1989.
			Bushman, F., and Craigie, R., "Activities of Human Immunodeficiency Virus (HIV) Integration Protein *In Vitro*: Specific Cleavage and Integration of HIV DNA," *Proc. Natl. Acad. Sci. USA* 88:1339-1343, Feb. 1991.
			Ciminale, V., *et al.*, "A Bioassay for HIV-1 Based on Env-CD4 Interaction," *AIDS Res. Hum. Retrovir.* 6(11):1281-1287, Nov. 1990. ABSTRACT ONLY
			Cohen, J., "The Daunting Challenge of Keeping HIV Suppressed," *Science* 277:32-33, July 1997.
			Cohen, K. A., *et al.*, "Characterization of the Binding Site for Nevirapine (BI-RG-587), a Nonnucleoside Inhibitor of Human Immunodeficiency Virus Type-1 Reverse Transcriptase," *J. Biol. Chem.* 266(22):14670-14674, Aug. 1991. ABSTRACT ONLY
			Condra, J. H., *et al.*, "Identification of the Human Immunodeficiency Virus Reverse Transcriptase Residues that Contribute to the Activity of Diverse Nonnucleoside Inhibitors," *Antimicrob. Agents Chemother.* 36(7):1441-1446, Jul. 1992. ABSTRACT ONLY
			De Clercq, E., "HIV Inhibitors Targeted at the Reverse Transcriptase," *AIDS Res. Hum. Retrovir.* 8(2):119-134, Feb. 1992. ABSTRACT ONLY

EXAMINER:	DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Docket: 4239-61858	App: 10/017,393
	Applicant: Rice *et al.*	
	Filed: December 13, 2001	Art Unit:

OTHER DOCUMENTS

			De Clercq, E., "What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections?," *Rev. Med. Virol.* 6(2):97-117, Jun. 1996.
			Debyser, Z., *et al.*, "An Antiviral Target on Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Revealed by Tetrahydroimidazo-[4,5,1-*jk*][1,4]benzodiazepin-2(1*H*)-one and –thione Derivatives," *Proc. Natl. Acad. Sci. USA.* 88:1451-1455, Feb. 1991.
			Finzi, D., *et al.*, "Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy," *Science* 278:1295-1300, Nov. 1997.
			Gao, H.Q., *et al.*, "Effects of Mutations in the Polymerase Domain on the Polymerase, RNase H and Strand Transfer Activities of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," *J. Mol. Biol.* 277:559-572, Apr. 1998. ABSTRACT ONLY
			Goldman, M. E., *et al.*, "Pyridinone Derivatives: Specific Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors With Antiviral Activity," *Proc. Natl. Acad. Sci. USA* 88:6863-6867, Aug. 1991.
			Goldman, M. E., *et al.*, "L-696,229 Specifically Inhibits Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Possesses Antiviral Activity *In Vitro*," *Antimicrob. Agents Chemother.* 36(5):1019-1023, May 1992. ABSTRACT ONLY
			Gonda, M.A., *et al.*, "Sequence Homology and Morphologic Similarity of HTLV-III and Visna Virus, a Pathogeni Lentivirus," *Science* 227:173-177, Jan. 1985.
			Gu, Zhengxian, *et al.*, "The K65R Mutant Reverse Transcriptase of HIV-1 Cross-Resistant to 2',3'-Dideoxycytidine, 2',3'-Dideoxy-3'-thiacytidine, and 2',3'-Dideoxyinosine Shows Reduced Sensitivity to Specific Dideoxynucleoside Triphosphate Inhibitors *In Vitro*," *J. Biol. Chem.* 269(45):28118-28122, Nov. 1994.

EXAMINER:	DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Docket: 4239-61858	App: 10/01[illegible]23
	Applicant: Rice *et al.*	
	Filed: December 13, 2001	Art Unit:

OTHER DOCUMENTS

			Howard, O.M., *et al.*, "Inhibition of *In Vitro* and *In Vivo* HIV Replication by a Distamycin Analogue That Interferes With Chemokine Receptor Function: a Candidate for Chemotherapeutic and Microbicidal Application," *J. Med. Chem.* 41(13):2184-2193, Jun. 1998. ABSTRACT ONLY
			Kimpton, J., and Emerman, M., "Detection of Replication-Competent and Pseudotyped Human Immunodeficiency Virus with a Sensitive Cell Line on the Basis of Activation of an Integrated Beta-Galactosidase Gene," *J. Virol.* 66(4):2232-2239, Apr. 1992. ABSTRACT ONLY
			Koup, R.A., *et al.*, "Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Replication by the Dipyridodiazepinone BI-RG-587," *J. Infect. Dis.* 163(5):966-970, May 1991. ABSTRACT ONLY
			Mellors, J.W., *et al.*, "Mutations in HIV-1 Reverse Transcriptase and Protease Associated with Drug Resistance," *Intl. Antiviral News* 3(1):8-13, 1995.
			Merluzzi, V. J., *et al.*, "Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor," *Science* 250:1411-1413, Dec. 1990.
			Miyasaka, T., *et al.*, "A Novel Lead for Specific Anti-HIV-1 Agents: 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine," *J. Med. Chem.* 32(12):2507-2509, Dec. 1989.
			Pauwels, R.K., *et al.*, "Potent and Highly Selective Human Immunodeficiency Virus Type 1 (HIV-1) Inhibition by a Series of α-Anilinophenylacetamide Derivatives Targeted at HIV-1 Reverse Transcriptase," *Proc. Natl. Acad. Sci. USA* 90:1711-1715, Mar. 1993.
			Pauwels, R., *et al.*, "Potent and Selective Inhibition of HIV-1 Replication *In Vitro* by a Novel Series of TIBO Derivatives," *Nature* 343(6257):470-474, Feb. 1990. ABSTRACT ONLY

EXAMINER:	DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Docket: 4239-61858	App: 10/017,323
	Applicant: Rice *et al.*	
	Filed: December 13, 2001	Art Unit: 1600/2900

OTHER DOCUMENTS

			Rice, W.G., *et al.*, "Inhibition of Multiple Phases of Human Immunodeficiency Virus Type 1 Replication by a Dithiane Compound That Attacks the Conserved Zinc Fingers of Retroviral Nucleocapsid Proteins," *Antimicrob. Agents Chemother.* 41(2):419-426, Feb. 1997.
			Rice, W.G., *et al.*, "Inhibition of HIV-1 Infectivity by Zinc-Ejecting Aromatic C-Nitroso Compounds," *Nature* 361(6411):473-475, Feb. 1993. ABSTRACT ONLY
			Rice, W.G., *et al.*, "Inhibitors of HIV Nucleocapsid Protein Zinc Fingers as Candidates for the Treatment of AIDS," *Science* 270:1194-1197, Nov. 1995.
			Rice, W.G., *et al.*, "Evaluation of Selected Chemotypes in Coupled in Coupled Cellular and Molecular Target-Based Screens Identifies Novel HIV-1 Zinc Finger Inhibitors," *J. Med. Chem.* 39(19):3606-3616, Sept. 1996. ABSTRACT ONLY
			Rice, W.G., *et al.*, "The Site of Antiviral Action of 3-Nitrosobenzamide on the Infectivity Process of Human Immunodeficiency Virus in Human Lymphocytes," *Proc. Natl. Acad. Sci. USA* 90:9721-9724, Oct. 1993.
			Rice, W.G., and Bader, J.P., "Discovery and *In Vitro* Development of AIDS Antiviral Drugs as Biopharmaceuticals," in *Adv. Pharmacol.* 33:389-438, 1995. ABSTRACT ONLY
			Romero, D.L., *et al.*, "Nonnucleoside Reverse Transcriptase Inhibitors That Potently and Specifically Block Human Immunodeficiency Virus Type 1 Replication," *Proc. Natl. Acad. Sci. USA* 88:8806-8810, Oct. 1991.
			Romero, D.L., *et al.*, "Bis(heteroaryl)piperazine (BHAP) Reverse Transcriptase Inhibitors: Structure-Activity Relationships of Novel Substituted Indole Analogues and the Identification of 1-[(5-Methanesulfonamido-1H-Indol-2-yl)-Carbonyl]-4-[3- [(1-Methylethyl)Amino]-Pyridinyl]piperazine Monomethanesulfonate (U-90152S), a Second-Generation Clinical Candidate," *J. Med. Chem.* 36(10):1505-1508, May 1993.

EXAMINER:	DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Docket: 4239-61858	App: 10/01[illegible]23
	Applicant: Rice *et al.*	
	Filed: December 13, 2001	Art Unit: 1800/2900

OTHER DOCUMENTS

			Ryabova *et al.*, "A New Approach to the Synthesis of 1,2- and 1,4-Dihydropyrido[3,2-*b*]indole Derivatives," *Mendeleev Commun.* 3:107-109, 1995.
			Ryabova *et al.*, "2-Formyl-3-Arylaminoindoles in the Synthesis of 1,2- and 1,4-Dihydro-5H-Pyrido[3,2-b]Indole (δ-Carboline) Derivates," *Pharm. Chem. J.* 30(9):579-584, 1996.
			Ryabova *et al.*, "2-Formyl-3-Arylaminoindoles in the Synthesis of 1,2- and 1,4-Dihydro-5H-Pyrido[3,2-b]Indole (δ-Carboline) Derivates," *Khimiko-Farmatsevticheskii Zhurnal*, 1996 (full citation unavailable). (Russian) THE RELEVANCE OF THIS REFERENCE IS AS SHOWN IN THE TITLE AND FIGURES 1-7.
			Ryabova *et al., Khimiko-Farmatsevticheskii Zhurnal,* pp. 42-46, 1996 (full citation unavailable). (Russian) THE RELEVANCE OF THIS REFERENCE IS AS SHOWN IN FIGURES 1-4.
			Turpin, J.A., *et al.*, "Reverse Transcription of Human Immunodeficiency Virus Type 1 is Blocked by Retroviral Zinc Finger Inhibitors," *Antiviral Chem. Chemother.* 8(1):60-69, 1997.
			Wallqvist, A., and Covell, D.G., "Docking Enzyme-Inhibitor Complexes Using a Preference-Based Free-Energy Surface," *Proteins* 25(4):403-419, 1996. ABSTRACT ONLY
			Weislow, O.S., *et al.*, "New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products for AIDS-Antiviral Activity," *J. Natl. Cancer Inst.* 81(8):577-586, Apr. 1989. ABSTRACT ONLY
			Wishka, D.G., *et al.*, "(-)-6-Chloro-2-[(1-furo[2, 3-c]pyridin-5-ylethyl)thio]-4-pyrimidinamine, PNU-142721, a New Broad Spectrum HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor," *J. Med. Chem.* 41(9):1357-1360, Apr. 1998.

EXAMINER:	DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Docket: 4239-61858	App: 10/017,233
	Applicant: Rice *et al.*	
	Filed: December 13, 2001	Art Unit:

OTHER DOCUMENTS

			Wong, J.K., *et al.*, "Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia," *Science* 278:1291-1295, Nov. 1997.
			Young, L. *et al.*, "A Role for Surface Hydrophobicity in Protein-Protein Recognition," *Prot. Sci.* 3:717-729, 1994.
			Zack, J.A., *et al.*, "HIV-1 Entry Into Quiescent Primary Lymphocytes: Molecular Analysis Reveals a Labile, Latent Viral Structure," *Cell* 61(2):213-222, Apr. 1990. ABSTRACT ONLY

EXAMINER:	DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.